Kura Oncology, Inc.

Kura Oncology, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of targeted oncology therapies. Headquartered in San Diego, California, the company's mission is to realize the promise of precision medicines to help cancer patients achieve better, longer lives.

The company's pipeline focuses on small molecule drug candidates designed to target specific cancer signaling pathways. Key product candidates include KOMZIFTI™ (ziftomenib), an FDA-approved, once-daily, oral menin inhibitor for relapsed or refractory NPM1-mutated acute myeloid leukemia (AML). Ziftomenib is also being evaluated in combination therapies for AML and gastrointestinal stromal tumors (GIST). Additionally, Kura Oncology is developing darlifarnib (KO-2806), an investigational next-generation farnesyl transferase inhibitor (FTI) in Phase 1 trials for clear cell renal cell carcinoma (RCC) in combination with cabozantinib, and other solid tumors. Another pipeline candidate, KO-7246, is a menin inhibitor being explored for diabetes, cardiometabolic diseases, and solid tumors.

Kura Oncology achieved a significant milestone with the FDA approval of KOMZIFTI (ziftomenib) for R/R NPM1-mutated AML in November 2025. The company has also reported positive data for darlifarnib combined with cabozantinib in clear cell renal cell carcinoma. Led by President, CEO, and Chairman of the Board Troy Wilson, Ph.D., J.D., who has been with the company since its inception in 2014, Kura Oncology is transitioning from a clinical-stage to a commercial-stage biopharmaceutical company. The company reported $2.1 million in Q4 2025 product revenue from KOMZIFTI and ended 2025 with a strong cash position of $667.2 million, providing a runway for its ongoing clinical programs.